Advanced

The SWENOTECA group: A good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway

Tandstad, Torgrim; Ståhl, Olof LU ; Håkansson, Ulf LU ; Wahlqvist, Rolf; Klepp, Olbjorn; Cavallin-Ståhl, Eva LU and Cohn-Cedermark, Gabriella (2016) In Scandinavian Journal of Urology2013-01-01+01:00 50(1). p.9-13
Abstract
Objective: The aim of this article is to present the Swedish and Norwegian Testicular Cancer Group (SWENOTECA), with an emphasis on the history of SWENOTECA, organization, results and current status. Materials and methods: SWENOTECA was founded in 1981 as a binational organization open to hospitals in Sweden and Norway treating testicular cancer. It has since published treatment protocols for testicular cancer and prospectively registered patients with testicular cancer. Today, all hospitals in Norway and Sweden involved in the care of testicular cancer participate in SWENOTECA, and all patients with testicular cancer are prospectively registered in a population-based database. Results: Nine protocols with standardized guidelines on the... (More)
Objective: The aim of this article is to present the Swedish and Norwegian Testicular Cancer Group (SWENOTECA), with an emphasis on the history of SWENOTECA, organization, results and current status. Materials and methods: SWENOTECA was founded in 1981 as a binational organization open to hospitals in Sweden and Norway treating testicular cancer. It has since published treatment protocols for testicular cancer and prospectively registered patients with testicular cancer. Today, all hospitals in Norway and Sweden involved in the care of testicular cancer participate in SWENOTECA, and all patients with testicular cancer are prospectively registered in a population-based database. Results: Nine protocols with standardized guidelines on the diagnosis, treatment and follow-up of testicular cancer have been published. In addition to the guidelines, several studies have been performed or initiated within the scope of SWENOTECA. The details are presented in this article. Conclusions: SWENOTECA has been a very fruitful binational collaboration and has thoughtfully evolved over time. The group's continuous work and dedication have provided an example for other national and international cancer networks. The binational implementation of standardized guidelines has resulted in excellent patient outcomes, regardless of place of residence. Although testicular cancer is a relatively rare disease, the population-based binational organization of SWENOTECA has made it possible to publish some of the largest studies in the field of testicular cancer. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cancer registry, SWENOTECA, testicular cancer
in
Scandinavian Journal of Urology2013-01-01+01:00
volume
50
issue
1
pages
9 - 13
publisher
Taylor & Francis
external identifiers
  • wos:000367832000003
  • scopus:84954113923
ISSN
2168-1813
DOI
10.3109/21681805.2015.1059360
language
English
LU publication?
yes
id
ef6b5f56-f0a5-445a-9b09-ca1391ec4325 (old id 8761214)
date added to LUP
2016-03-01 07:18:21
date last changed
2017-10-29 03:21:00
@article{ef6b5f56-f0a5-445a-9b09-ca1391ec4325,
  abstract     = {Objective: The aim of this article is to present the Swedish and Norwegian Testicular Cancer Group (SWENOTECA), with an emphasis on the history of SWENOTECA, organization, results and current status. Materials and methods: SWENOTECA was founded in 1981 as a binational organization open to hospitals in Sweden and Norway treating testicular cancer. It has since published treatment protocols for testicular cancer and prospectively registered patients with testicular cancer. Today, all hospitals in Norway and Sweden involved in the care of testicular cancer participate in SWENOTECA, and all patients with testicular cancer are prospectively registered in a population-based database. Results: Nine protocols with standardized guidelines on the diagnosis, treatment and follow-up of testicular cancer have been published. In addition to the guidelines, several studies have been performed or initiated within the scope of SWENOTECA. The details are presented in this article. Conclusions: SWENOTECA has been a very fruitful binational collaboration and has thoughtfully evolved over time. The group's continuous work and dedication have provided an example for other national and international cancer networks. The binational implementation of standardized guidelines has resulted in excellent patient outcomes, regardless of place of residence. Although testicular cancer is a relatively rare disease, the population-based binational organization of SWENOTECA has made it possible to publish some of the largest studies in the field of testicular cancer.},
  author       = {Tandstad, Torgrim and Ståhl, Olof and Håkansson, Ulf and Wahlqvist, Rolf and Klepp, Olbjorn and Cavallin-Ståhl, Eva and Cohn-Cedermark, Gabriella},
  issn         = {2168-1813},
  keyword      = {Cancer registry,SWENOTECA,testicular cancer},
  language     = {eng},
  number       = {1},
  pages        = {9--13},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Urology2013-01-01+01:00},
  title        = {The SWENOTECA group: A good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway},
  url          = {http://dx.doi.org/10.3109/21681805.2015.1059360},
  volume       = {50},
  year         = {2016},
}